Circumventing cancer drug resistance in the era of personalized medicine
All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the...
Gespeichert in:
Veröffentlicht in: | Cancer discovery 2012-03, Vol.2 (3), p.214-226 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 226 |
---|---|
container_issue | 3 |
container_start_page | 214 |
container_title | Cancer discovery |
container_volume | 2 |
creator | Garraway, Levi A Jänne, Pasi A |
description | All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s).
Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways. |
doi_str_mv | 10.1158/2159-8290.CD-12-0012 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1013919897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1013919897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0Eoqj0DxDykk3K2I6TeIlSoEiV2MDacpxxMUqTYidI8PUkaulsZnR153UIuWGwZEwW95xJlRRcwbJcJYwnAIyfkauTfH6q83RGFjF-whipSiXkl2TGuSykUuKKrEsf7LD7xrb37ZZa01oMtA7DlgaMPvaTQH1L-w-kGAztHN1jiF1rGv-LNd1h7a1v8ZpcONNEXBzznLw_Pb6V62Tz-vxSPmwSm-bQJ5lRzIgCxiMFVlI5tBYqVchKQu0YzzKRWsnBGgeSC5GjyCFzaQ1WQIFOzMndYe4-dF8Dxl7vfLTYNKbFboiaAROKqULlozU9WG3oYgzo9D74nQk_o0lPGPXESE-8dLnSjOsJ49h2e9wwVON3p6Z_aOIPIn5s6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1013919897</pqid></control><display><type>article</type><title>Circumventing cancer drug resistance in the era of personalized medicine</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>Garraway, Levi A ; Jänne, Pasi A</creator><creatorcontrib>Garraway, Levi A ; Jänne, Pasi A</creatorcontrib><description>All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s).
Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.</description><identifier>ISSN: 2159-8274</identifier><identifier>EISSN: 2159-8290</identifier><identifier>DOI: 10.1158/2159-8290.CD-12-0012</identifier><identifier>PMID: 22585993</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - therapeutic use ; Drug Resistance, Neoplasm ; Humans ; Neoplasms - drug therapy ; Neoplasms - genetics ; Neoplasms - metabolism ; Precision Medicine - methods</subject><ispartof>Cancer discovery, 2012-03, Vol.2 (3), p.214-226</ispartof><rights>2012 AACR.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</citedby><cites>FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3342,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22585993$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garraway, Levi A</creatorcontrib><creatorcontrib>Jänne, Pasi A</creatorcontrib><title>Circumventing cancer drug resistance in the era of personalized medicine</title><title>Cancer discovery</title><addtitle>Cancer Discov</addtitle><description>All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s).
Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Drug Resistance, Neoplasm</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - metabolism</subject><subject>Precision Medicine - methods</subject><issn>2159-8274</issn><issn>2159-8290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0Eoqj0DxDykk3K2I6TeIlSoEiV2MDacpxxMUqTYidI8PUkaulsZnR153UIuWGwZEwW95xJlRRcwbJcJYwnAIyfkauTfH6q83RGFjF-whipSiXkl2TGuSykUuKKrEsf7LD7xrb37ZZa01oMtA7DlgaMPvaTQH1L-w-kGAztHN1jiF1rGv-LNd1h7a1v8ZpcONNEXBzznLw_Pb6V62Tz-vxSPmwSm-bQJ5lRzIgCxiMFVlI5tBYqVchKQu0YzzKRWsnBGgeSC5GjyCFzaQ1WQIFOzMndYe4-dF8Dxl7vfLTYNKbFboiaAROKqULlozU9WG3oYgzo9D74nQk_o0lPGPXESE-8dLnSjOsJ49h2e9wwVON3p6Z_aOIPIn5s6w</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Garraway, Levi A</creator><creator>Jänne, Pasi A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Circumventing cancer drug resistance in the era of personalized medicine</title><author>Garraway, Levi A ; Jänne, Pasi A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Drug Resistance, Neoplasm</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - metabolism</topic><topic>Precision Medicine - methods</topic><toplevel>online_resources</toplevel><creatorcontrib>Garraway, Levi A</creatorcontrib><creatorcontrib>Jänne, Pasi A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garraway, Levi A</au><au>Jänne, Pasi A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circumventing cancer drug resistance in the era of personalized medicine</atitle><jtitle>Cancer discovery</jtitle><addtitle>Cancer Discov</addtitle><date>2012-03</date><risdate>2012</risdate><volume>2</volume><issue>3</issue><spage>214</spage><epage>226</epage><pages>214-226</pages><issn>2159-8274</issn><eissn>2159-8290</eissn><abstract>All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s).
Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.</abstract><cop>United States</cop><pmid>22585993</pmid><doi>10.1158/2159-8290.CD-12-0012</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2159-8274 |
ispartof | Cancer discovery, 2012-03, Vol.2 (3), p.214-226 |
issn | 2159-8274 2159-8290 |
language | eng |
recordid | cdi_proquest_miscellaneous_1013919897 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research |
subjects | Antineoplastic Agents - therapeutic use Drug Resistance, Neoplasm Humans Neoplasms - drug therapy Neoplasms - genetics Neoplasms - metabolism Precision Medicine - methods |
title | Circumventing cancer drug resistance in the era of personalized medicine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A42%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circumventing%20cancer%20drug%20resistance%20in%20the%20era%20of%20personalized%20medicine&rft.jtitle=Cancer%20discovery&rft.au=Garraway,%20Levi%20A&rft.date=2012-03&rft.volume=2&rft.issue=3&rft.spage=214&rft.epage=226&rft.pages=214-226&rft.issn=2159-8274&rft.eissn=2159-8290&rft_id=info:doi/10.1158/2159-8290.CD-12-0012&rft_dat=%3Cproquest_cross%3E1013919897%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1013919897&rft_id=info:pmid/22585993&rfr_iscdi=true |